PubMed 1 March 2022
Use of CCTA or a CCTA-based clinical risk score to guide preventative therapy
There is a growing need to improve the risk stratification of patients with suspected atherosclerotic cardiovascular disease (ASCVD). “As CCTA becomes more widely utilised, an opportunity exists to offer patients (obstructive and non-obstructive) a more personalised assessment of ASCVD risk to optimise allocation of lipid lowering therapy” (Jaltotage, 2022). This has the potential to improve patient management through individualisation.
Artrya’s Chief Medical Officer, Prof. Dwivedi, explores the use of CCTA or a CCTA-based clinical risk score to guide preventative therapy in his latest study.